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http://arthritis-research.com/content/15/6/R195RESEARCH ARTICLE Open AccessRheumatoid arthritis patients are not at increased
risk for 30-day cardiovascular events, infections,
or mortality after total joint arthroplasty
Kaleb Michaud1,2,3, Edward V Fehringer3, Kevin Garvin3, James R O’Dell1,3 and Ted R Mikuls1,3,4*Abstract
Introduction: Serious infection, cardiovascular disease, and mortality are increased in rheumatoid arthritis (RA).
Whether RA affects the risk for these complications after total joint arthroplasty (TJA) is unknown, we hypothesize
that it does. We compared the occurrence of 30-day postoperative complications and mortality in a large cohort of
RA and osteoarthritis (OA) patients undergoing hip or knee TJA.
Methods: Analyses included 7-year data from the Veterans Affairs Surgical Quality Improvement Program. The 30-day
complications were compared by diagnosis by using logistic regression, and long-term mortality was examined by
using Cox proportional hazards regression. All analyses were adjusted for age, sex, and clustering by surgical site.
Additional covariates included sociodemographics, comorbidities, health behaviors, and operative risk factors.
Results: The 34,524 patients (839 RA, 33,685 OA) underwent knee (65.9%) or hip TJA. Patients were 95.7% men with a
mean (SD) age of 64.4 (10.7) years and had 3,764 deaths over a mean follow-up of 3.7 (2.3) years. Compared with OA
patients, those with RA were significantly more likely to require a return to the operating room (odds ratio (OR), 1.45
(95% CI, 1.08 to 1.94), but had similar rates of 30-day postoperative infection, OR 1.02 (0.72 to 1.47), cardiovascular
events, OR 0.69 (0.37 to 1.28), and mortality, OR 0.94 (0.38 to 2.33). RA was associated with a significantly higher
long-term mortality; hazard ratio (HR), 1.22 (1.00 to 1.49).
Conclusion: In this study of US veterans, RA patients were not at an increased risk for short-term mortality or other
major complications after TJA, although they returned to the operating room more often and had increased long-term
mortality.Introduction
Total joint arthroplasty (TJA) is among the most com-
monly performed elective surgeries, with more than a
million total knee and hip arthroplasties completed in
the United States in 2010 alone [1]. Overall charges in
the United States for knee TJA in 2005 were US$8.85
billion [2,3]. With a rapidly aging population, coupled
with increasing arthritis prevalence [4] and an escalation
in the use of TJA [5-7], these numbers are expected to
grow exponentially over the next few decades. Numer-
ous investigations have detailed the substantial benefit
of TJA in the treatment of end-stage arthropathy, bene-
fits that include significant pain relief and improved* Correspondence: tmikuls@unmc.edu
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reproduction in any medium, provided the orfunctional status. Whereas general acceptance exists re-
garding the efficacy of TJA in end-stage arthritis, signifi-
cant controversy surrounds the selection of patients who
are most likely to benefit from joint-replacement surgery
and, conversely, which patients are most likely to experi-
ence serious postoperative complications. Specifically, lim-
ited studies have examined the impact of TJA on overall
mortality [8-15].
In addition to a focus on important clinical improve-
ments in pain and function, most studies examining
arthroplasty outcomes have exclusively involved patients
with osteoarthritis (OA) because of its greater preva-
lence. The underrepresentation of patients with other
forms of arthritis is highly relevant because TJA has
been widely adopted as a therapeutic approach in other
conditions, including rheumatoid arthritis (RA). Esti-
mates suggest that approximately 18% to 25% of RAal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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20 years [16,17]. RA patients have a higher prevalence
than non-RA patients of selected comorbidities (that is,
cardiovascular disease and serious infection) that could
render this population at higher risk for serious postop-
erative complications after TJA. A recent systematic
review of complications after TJA in RA and OA
highlighted the need for more studies investigating
these differences, most notably in infections, as their
study hinted at increased risks in RA and mortality,
for which most studies were underpowered [18].
In the present study, we assessed 30-day postoperative
status, including cardiovascular events and infections,
for a large population of patients with RA and OA
undergoing initial TJA of the knee and hip. With a pau-
city of previous studies examining outcomes after TJA
in RA, we also sought to identify patient factors associ-
ated with worse outcomes in this at-risk population.
Methods
Study subjects
Study subjects included patients in the Veterans Affairs
Surgical Quality Improvement Program (VASQIP) data-
base from years 1999 through 2006. VASQIP is a vali-
dated prospective quality-assurance and data-collection
program that includes comprehensive data from surgeries
performed under either general or epidural anesthesia
[19,20]. An assessment of VASQIP has shown the data-
collection efforts to be highly reliable, with >73% of data
elements having substantial or almost perfect agreement
with other surgical datasets [21]. As previously described,
the database includes data on preoperative risk variables,
intraoperative variables, and postoperative outcomes,
including all-cause mortality [22]. The present study
included surgical data from 106 collection sites from
patients undergoing their first TJA of the hip or knee dur-
ing the observation period. Total hip and knee arthroplas-
ties were defined by using Current Procedural Terminology
(CPT) codes of 27310 and 27447, respectively. Patients
undergoing emergency surgery were excluded.
The VASQIP database was linked to outpatient and
inpatient pharmacy dispensing data from the VA
Pharmacy Benefits Management (PBM) database for
the 1-year period preceding the index surgery. Linked
PBM data also included all inpatient and outpatient
ICD9 diagnoses for 1 year preceding surgery. Patients
were classified as having RA if they had (a) at least one
diagnostic code for RA (714.0) and (b) use of at least one
biologic or nonbiologic DMARD during the 1-year pre-
operative period. This definition has previously been
shown to have sensitivity/specificity exceeding 80% for
identifying patients with RA [23]. Patients were catego-
rized as having OA if they had at least one diagnostic code
for OA (715.0 to 715.9), received no DMARDs 1 yearbefore surgery, and lacked ICD9 codes for RA or alterna-
tive inflammatory arthritides (099.3, 555.9, 696.0, 710.0,
711.1*, 714.*, and 720.*). Patients who met only one of
the two requirements for RA diagnosis, irrespective of
OA diagnosis, were excluded from primary analysis.
The Institutional Review Board and the Research &
Development Committee at the Omaha VA Medical
Center, in addition to the VASQIP Executive Committee,
approved this protocol.
Postoperative status and outcomes
Primary outcomes for the study were simplified into one
continuous and several dichotomous variables: postoperative
stay at hospital in days; return to the operating room; any
complications [20]; any cardiovascular complications (cardiac
arrest requiring CPR, myocardial infarction, cerebrovascular
accident, pulmonary embolism, or deep-vein thrombosis);
any infection complications (systemic sepsis, pneumonia,
urinary tract infection, superficial surgical-site infection,
and deep wound surgical-site infection); and mortality
status.
Personnel in the VASQIP Data Center determined vital
status by cross-matching these data with veteran death re-
cords in the Beneficiary Identification of Records Locator
System (BIRLS) of the Veterans Benefits Administration.
This system identifies all deaths, regardless of cause, af-
fecting VA beneficiaries [21]. We defined short-term mor-
tality status as mortality within 30 days of surgery. We
obtained date of death through December 31, 2006.
Predictors of postoperative outcomes
In addition to the specific type of TJA and arthritis diag-
nosis (RA versus OA), several potential determinants of
postoperative outcomes included both preoperative and
intraoperative factors [21]. Preoperative factors exam-
ined included age, gender, race, smoking status, diabetes
mellitus, alcohol use, chronic obstructive pulmonary dis-
ease (COPD), patient-reported dyspnea, congestive heart
failure (CHF), cerebrovascular disease, chronic gluco-
corticoid use, American Society of Anesthesiologists
(ASA) class (dichotomized as healthy/mild versus severe/
very severe), functional health status rated by dependency,
and inclusive calendar 2-year of procedure categorized as
1999 through 2000, 2001 through 2002, 2003 through
2004, and 2005 through 2006.
Additional preoperative risk factors examined included
seven selected laboratory abnormalities: blood urea ni-
trogen >40 mg/dl, creatinine >1.2 mg/dl, hematocrit ≤38%,
platelet count ≤150,000/μl, serum sodium ≤135 or >
145 mM, or white blood cell count >11,000/μl.
Intraoperative factors examined included total opera-
tive time and anesthesia type. Potential predictor vari-
ables that were missing for more than 15% of patients
were excluded (for example, do-not-resuscitate status,
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thrombin time, and partial thromboplastin time). In
addition, we excluded possible preoperative predictor
variables that were abnormal or prevalent in ≤0.9% of
patients (for example, weight loss, diagnosis of dissemi-
nated malignancy, impaired sensorium, central nervous
system tumor, wound infection, or open wound) after
confirming that no significant prevalence differences
existed between RA and OA.
Although VASQIP records if the patient is taking
glucocorticosteroids (GCSs) before surgery, we thought
greater understanding of the patient’s GCS history
could be important for surgical outcomes. By using
the VA PBM, we identified patients that were dispensed
the GCSs dexamethasone, hydrocortisone, prednisolone,
prednisone, or methylprednisolone at 30 days, 6 months,
and 1 year before TJA surgery. We also identified
patients who were dispensed GCS 10 days before
surgery to account for possible perioperative stress
dosing.
Statistical analysis
Descriptive and comparative analysis was conducted by
using the t test for continuous measures and a test of
difference between two proportions for dichotomous
measures. We conducted multivariable logistic and lin-
ear regressions with backward stepwise selection for
analyzing each outcome of interest, with age, sex, and
TJR type kept in every model. All regressions clustered
patients by surgical site.
Short-term mortality analysis used a similar model
with multivariable logistic regression of mortality status
at 30, 180, or 365 days after surgery. Longitudinal mor-
tality analysis was conducted by using Cox proportional
hazards regression models, with the surgery date as the
initial date for mortality risk until the date or death or
censorship at December 31, 2006.
Data were analyzed by using Stata (College Station,
TX, USA) version 11.1. Statistical significance was set at
the 0.05 level; confidence intervals were established at
95%; and all tests were two-tailed.
Results
Patient characteristics
Of the 34,524 patients included in our primary analysis,
only 839 (2.4%) had a qualifying RA diagnosis, with the
remaining 33,685 (97.6%) having OA. Most surgeries
were total knee arthroplasties (TKAs) (65.9%), and the
average (SD) length of stay was 7.7 (7.3) days. Table 1
shows the characteristics of the patients by diagnosis. In
comparison with OA patients, RA patients were youn-
ger, more likely to be female and Caucasian, and less
likely to consume alcohol. No significant differences
were found in smoking status. RA patients were lesslikely to have diabetes mellitus, although they were more
likely to be rated with poor functional health.
Several DMARDs were taken by RA patients before
surgery, including methotrexate (58.6%), hydroxychloro-
quine (40.4%), biologics (24.0%), and sulfasalazine
(23.2%). By definition of diagnosis group, none of the
OA patients was taking a DMARD. RA patients were
much more likely to be taking GCS and chemotherapy
and less likely to be taking low-dose aspirin before sur-
gery (Table 1).
A large number of patients were missing several pre-
operative laboratory measures, with only 10,673 patients
(10,387 OA and 286 RA) having all 13 values available
(Additional file 1: Table S1). This group was studied in a
separate analysis that included all laboratory values, as
abnormalities may have been associated with other co-
morbidities or alerted the surgeon to take precautionary
measures. Of the preoperative laboratory values used in
the primary analysis, 7.3% of patients were missing at
least one of the seven values examined.
TJA complications
We examined the association of all covariates on several
surgical-complication outcomes (Table 2) in multivari-
able regressions. A post-operative cardiovascular event
occurred in 2.0% of patients, and although it was associ-
ated with risk factors such as age, time of operation,
COPD, dyspnea, preoperative wound or infection, transi-
ent ischemic attack (TIA) history, and creatinine
>1.2 mg/dl clearance, factors including male sex and RA
versus OA were not significantly associated (Table 3).
Even more covariates were linked with postoperative in-
fections, including the receipt of diabetes treatments, fe-
male sex, and poor functional health, although again, RA
diagnosis had no association and, unexpectedly, GCS
dispensing in the month before TJA was protective (OR,
0.75 (95% CI, 0.58 to 0.96)). Deep-wound surgical infec-
tions had similar associations, although a positive associ-
ation was noted with dispensing in the 6 months before
surgery (OR, 1.86 (1.33to 2.60)). Considering all post-
TJR complications, neither an association with RA diag-
nosis nor one with the specific target joint being re-
placed was found, as shown in Table 3.
In similar analysis, length of hospital stay in days dur-
ing TJA was increased by a day for each decade of age,
another day for each hour of surgery, and a half-day for
having hip (versus knee) surgery, and was decreased a
day for men and for every 3 calendar years. No associ-
ation was found between having RA with this length of
hospital stay, although having CHF, stroke, diabetes,
COPD, GCS use in the past year, and poor functional
status were all associated with an increased length of
stay. When looking at any return to the operating room
within 30 days of TJA, RA patients were 40% more likely
Table 1 Characteristics of VA VASQIP patients receiving TKA or THA by OA or RA diagnosis
OA (n = 33,685) RA (n = 839) P-value
Missing Mean SD Missing Mean SD
Demographics and comorbidity
Age (years) 0 64.49 10.72 0 62.19 10.55 <0.001
Male sex (%) 0 95.73 0 93.09 <0.001
Caucasian (%) 2,236 72.73 49 76.08 0.037
Alcohol consumption (%) 348 7.66 6 4.08 <0.001
Current smoker (%) 204 24.23 3 22.85 0.356
Diabetes mellitus (%) 204 16.88 3 12.20 <0.001
COPD (%) 1 9.67 1 10.74 0.301
Operation time (hours) 1 2.26 0.76 0 2.29 0.77 0.248
Low-dose aspirin (%) 0 38.09 0 27.89 <0.001
Poor functional health (%) 0 5.28 0 9.06 <0.001
Short of breath, dyspnea ≥2 (%) 274 11.17 8 9.63 0.162
General anesthesia (%) 0 69.39 0 70.92 0.343
Bleeding disorders (%) 206 1.34 4 1.44 0.812
Chemotherapy <30 days pre-op (%) 206 0.22 5 3.60 <0.001
CHF <30 days pre-op (%) 3 0.77 1 0.84 0.820
TIA history (%) 211 2.18 4 2.04 0.773
CVA/Stroke with neurologic deficit (%) 209 2.02 4 1.44 0.234
CVA/Stroke without neurologic deficit (%) 209 2.29 4 2.75 0.375
GCS use before surgery
≤30 days 0 5.70 0 49.94 <0.001
≤0.5 year 0 11.68 0 62.22 <0.001
≤1 year 0 16.03 0 67.70 <0.001
At surgery interview (VASQIP) 0 1.16 0 41.12 <0.001
VASQIP or ≤1 year 0 16.42 0 69.25 <0.001
VASQIP and ≤1 year 0 0.77 0 39.45 <0.001
Abnormal pre-op laboratory
Hematocrit ≤38% (%) 693 15.43 13 30.51 <0.001
White blood cells >11,000/μl (%) 890 3.85 16 10.45 <0.001
Platelets ≤150,000/μl (%) 1,175 5.71 20 3.30 0.003
Creatinine >1.2 mg/dl (%) 1,533 31.33 34 23.85 <0.001
Serum sodium ≤135 mM (%) 1,905 7.24 43 8.54 0.163
Serum sodium >145 mM (%) 1,905 1.63 43 1.01 0.165
Blood urea nitrogen >40 mg/dl (%) 2,990 0.93 80 0.79 0.689
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1.90)), as were those receiving hip versus knee surgery
(OR, 1.38 (1.17 to 1.63)). No analyses showed an associ-
ation of removing or separating patients who had GCS
use within 10 days before surgery from those patients
who took GCS in larger time windows beforehand.
We repeated these analyses for the subset of 10,673
patients with full laboratory data. Except for the length
of stay, for which RA patients had a significantly de-
creased stay of −0.97 (−1.82 to −0.12) days, none of theother TJA outcomes had appreciable differences in mag-
nitude between RA and OA.
TJA mortality
In total, 3,764 deaths over a mean follow-up of 3.7 (2.3)
years occurred in the analysis cohort. Mortality was ini-
tially examined in models similar to other complications,
although at three discrete time points after TJA. At no
point up to 1 year was there a statistically important dif-
ference between RA and OA, although after covariate
Table 2 Surgical outcomes of patients receiving TKA or THA by OA or RA diagnosis
OA (n = 33,685) RA (n = 839) P value
Missing Mean SD Missing Mean SD
Outcome
Postoperative stay (days) 130 7.77 7.31 7 7.77 5.79 0.994
Return to operating room (%) 0 3.06 0 4.53 0.015
Any complications? (%) 0 7.04 0 6.67 0.679
Any PO CV event (%) 0 2.04 0 1.31 0.139
Any PO infection (%) 0 4.15 0 4.17 0.972
Superficial surgical-site infection (%) 0 1.10 0 1.19 0.798
Deep wound surgical-site infection (%) 0 0.65 0 0.36 0.291
TJR type
Hip (%) 0 34.19 0 31.35 0.087
Knee (%) 0 65.80 0 68.70 0.087
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mortality for RA over time: 30-day OR 0.94 (0.38 to
2.33), 6-month OR, 1.25 (0.72 to 2.19), and 1-year OR,
1.30 (0.87 to 1.96).
When examining mortality over time continuously
until 2007 by using Cox proportional hazards regression,
RA patients had a hazard ratio (HR) of 1.22 (1.00 to
1.49). Associated covariates were similar to the prior di-
chotomous mortality analysis, and the full model is
shown in Table 3. The Kaplan-Meier curve and adjusted
survival function for this full model by diagnosis are
shown in Figure 1.
Discussion
Covering 8 years in 106 VA surgical sites, our sizable
study analyzed and compared the experiences of 34,524
OA and RA patients receiving their initial total knee- or
hip-replacement surgery. No associations with RA versus
OA were found for surgical complications, including
cardiovascular and infectious events occurring within
30 days of the surgery. Whereas we found no association
of RA with length of hospital stay, patients were signifi-
cantly more likely to return to the operating room
within 30 days of their TJA. Mortality remained similar
for RA and OA after TJR, except for the increase in RA
when we allowed a time horizon beyond 1 year after
surgery.
Although our study is the second to use the VASQIP
database to examine the impact of patient and surgery
covariates on TKA and THA outcomes, the prior study
by Weaver et al. [19] reported on data from 1991 to
1997, all before the current study’s start date of 1999,
and did not have several of the measures we analyzed,
including RA diagnosis. They did not find alcohol use to
be significantly associated with postsurgical complica-
tions, in contrast with results from our study, which is
consistent with a more recent analysis of VASQIP [24].We previously analyzed a portion of the current data,
comparing outcomes for total shoulder arthroplasty with
TKA and THA, which provides an alternative view of
the current study [25]. Both the study of Weaver et al.
and our study complement each other and provide
useful tools for determining the risk of postoperative
complications by an individual patient’s characteris-
tics, which is especially useful as the number of TJAs
increases in the aging general and VA population.
Whereas the overall rates of TJA increase, the rates in
RA patients have been decreasing in past decades, likely
because of improvements in treatments, although TJA
still represents an important outcome in the failure to
control progressive joint damage from RA [8,16,26]. Al-
though patients undergoing TJA have been reported to
have a greater risk of surgical complications, our study
did not find evidence of this. Whether orthopedic sur-
geons take greater preventative care when operating on
RA patients or whether they postpone this often-elective
procedure to a time (or indefinitely) with the least amount
of RA activity, the current study’s observational data can-
not address this, and we are left speculating.
A few studies have shown increased risk of TJA joint
infection in RA versus OA patients [27,28], although all
had a much longer follow-up in comparison to that of
the current study, which found no statistically significant
increased risk of 30-day infection in RA patients.
Bongartz et al. [28] found 1.2% of 657 TJAs in RA
had infection within 30 days, which is the same rate that
we found for our superficial site infection, but much
higher than our deep-wound site infection (0.4%). Al-
though we also controlled for age, sex, function, comor-
bidities, prior infection, and more, we found no increase
in RA infections; this difference may be because our popu-
lation all had primary surgery, whereas they found most
of their infections in TJA revision [28]. We did find
contradictory results in the impact of GCS on overall
Table 3 Multivariable logistic-regression model results for complications associated with hip or knee TJAa
Variable Any post-op
cardiovascular event
Any post-op infection Deep wound
surgical-site infection
Any complications Post- tay
(β in ys)
Return to operating
room within 30 days
Mortalityb
RA versus OAc 0.66 (0.35, 1.24) 1.14 (0.80, 1.62) 0.35 (0.12, 1.08) 1.07 (0.80, 1.43) −0.18 (− , 0.38) 1.41 (1.05, 1.90) 1.22 (1.00, 1.49)
Agec 1.03 (1.02, 1.04) 1.03 (1.02, 1.03) 0.99 (0.98, 1.01) 1.02 (1.02, 1.03) 0.10 (0 0.12) 1.00 (0.99, 1.01) 1.06 (1.05, 1.06)
Male sexc 1.04 (0.66, 1.64) 0.68 (0.53, 0.87) 0.77 (0.46, 1.29) 0.8 (0.67, 0.95) −1.06 (− , -0.61) 1.05 (0.78, 1.42) d
Hip versus knee TJAc 0.88 (0.73, 1.05) 1.10 (0.96, 1.26) 0.96 (0.68, 1.35) 1.10 (0.99, 1.23) 0.62 (0 0.90) 1.38 (1.17, 1.63) 1.24 (1.16, 1.33)
Operation Time (in hours) 1.10 (1.00, 1.22) 1.11 (1.01, 1.23) 1.22 (1.04, 1.43) 1.16 (1.08, 1.24) 1.10 (0 1.45) 1.23 (1.13, 1.33) 1.30 (1.19, 1.41)
General anesthesia 1.17 (1.00, 1.39) 1.43 (0.98, 2.10) 1.17 (1.04, 1.32)
Calendar year (1998–2006) 1.03 (1.00, 1.07) −0.28 (− , -0.18)
Caucasian race −0.98 (− , -0.28)
Alcohol consumption 1.19 (1.02, 1.39) 1.23 (1.09, 1.38)
Current smoker 0.78 (0.62, 1.00) 1.72 (1.30, 2.26) 1.57 (1.45, 1.71)
Poor functional health 1.48 (1.20, 1.81) 1.66 (1.07, 2.58) 1.62 (0 2.46) 1.42 (1.13, 1.78)
Short of breath, dyspnea ≥2 1.53 (1.22, 1.93) 1.27 (1.10, 1.47) 1.36 (1.10, 1.66) 1.20 (1.09, 1.32)
COPD history 1.27 (1.01, 1.60) 1.81 (1.52, 2.16) 1.47 (1.27, 1.70) 0.54 (0 0.87) 1.45 (1.32, 1.60)
Bleeding disorder 2.34 (1.63, 3.37) 1.83 (1.28, 2.62)
Pre-op open wound/infection 3.02 (1.28, 7.13) 2.46 (1.32, 4.60) 2.73 (1.62, 4.61) 2.86 (1.53, 5.35) 1.91 (1.20, 3.04)
TIA history 2.03 (1.46, 2.81) 1.41 (1.11, 1.79)
Stroke history w/impairment 1.23 (0 1.96)
Stroke history w/o impairment 1.49 (1.00, 2.21) 1.21 (1.02, 1.44)
CHF <30 days pre-op 1.53 (1.02, 2.29) 2.54 (0 4.47) 1.55 (1.22, 1.96)
Impaired sensorium 2.30 (1.61, 3.28)
Diabetes: oral treatment 1.18 (1.02, 1.37) 1.59 (1.14, 2.21) 1.2 (1.05, 1.37)
Diabetes: insulin treatment 1.36 (1.09, 1.69) 2.48 (1.65, 3.73) 1.41 (1.18, 1.70)
Diabetes: oral or insulin 0.40 (0 0.64)
Chemotherapy <30 days preop 1.72 (1.19, 2.49)
Low-dose aspirin 0.76 (0.64, 0.90) 0.47 (0.33, 0.67) 0.77 (0.68, 0.88) 0.71 (0.62, 0.82) 0.65 (0.60, 0.70)
White blood cells >11,000/μl 1.35 (1.16, 1.56)
Creatinine >1.2 mg/dl 1.20 (1.00, 1.44)
Hematocrit ≤38% 1.21 (1.04, 1.42) 1.25 (1.12, 1.40) 1.47 (1.36, 1.58)





























Table 3 Multivariable logistic-regression model results for complications associated with hip or knee TJAa (Continued)
GCS (30 days) 0.75 (0.58, 0.96) 0.82 (0.69, 0.97)
GCS (6 months) 1.86 (1.33, 2.60)
GCS (1 year) 0.45 (0.18, 0.72)
GCS (VASQIP) 1.52 (1.26, 1.82)
Constant 557.9
aExcept where noted, odds ratios (95% CI).
bCox proportional hazards regression, hazard ratios (95% CI).
cVariable was forced into all models.
dNot significant and removed for not meeting proportional hazard requirement.
















Figure 1 Mortality after total joint arthroplasty by rheumatoid arthritis (RA) and osteoarthritis (OA) diagnosis through (A) Kaplan-Meier
curves with 95% confidence intervals and (B) Cox proportional hazards regression model adjusted for 16 covariates listed in Table 3.
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used less than 30 days before surgery (OR, 0.75 (0.58
to 0.96)), and deep-wound infections, which were as-
sociated with GCS when dispensed less than 6 months
beforehand (1.86 (1.33 to 2.60)). It is difficult to inter-
pret this without access to dosage of GCS, but it is
likely that a bias exists for near-TJA surgical date pre-
scription compared with longer-term prescriptions,
which have been shown to have a near-exponential
dose-time impact on future infections [29].
The systematic review by Singh and colleagues [10]
addressed mortality after TKA and THA. They found
no significant difference in 30-day and 90-day mortal-
ity between RA and OA patients, although they indi-
cated that this may be due to the small number of
studies reporting these data (for example, a total of
four deaths in 481 RA patients at 90 days). We sus-
pect that all 20 of their reported 30-day mortality events
(of 7,174 RA patients) came from one surgical site’s re-
cords during 1969 through 1997 [13,15], all before the
dates of the current study. Similar power issues are found
with the Ravi et al. [18] systematic review that showed no
difference in mortality.
Domsic et al. [30] looked at mortality during the
hospital stay for TKA and THA by using the large
Nationwide Inpatient Sample from 1993 through
2006. They reported similar results that mortality in
RA was no different from that in their non-lupus and
non-RA controls, although in several multivariable
subanalyses, they found RA to be protective of mor-
tality for all elective surgeries: OR, 0.58 (95% CI, 0.41
to 0.82), and for all TKA, OR, 0.64 (0.44 to 0.92).
The reasons for these findings are not clear, although
their average length of hospital stay was 2 to 3 days
shorter than ours, and they had a greater RA versus
OA age difference.A limitation of our study is the relatively low ratio of
RA to OA patients (2.4%), which reduced our power to
detect less-robust associations, although this is likely re-
lated to the substantially increased number of men in
the VA system, compared with the average clinical popu-
lation, who are less likely than women to develop RA.
Recognizing these limitations, our study results are still
based on a considerable number of surgeries, making it
one of the largest studies of its kind to date. Although
important RA covariates of clinical disease activity were
not available, our study did include the possible impact
of RA treatments like GCS, along with comorbidities
that are often associated with worse disease and infec-
tions [29]. Our data unfortunately did not record the
reason for a return to the operating room, and we must
speculate whether this was due to dislocations or other
causes.
This highlights another limitation, that our study relies
up the patient diagnosis and classification of a large
registry and that we were unable to validate the reported
outcomes or review the patient records, although this is
true of almost all administrative data studies.
The important risk factor of obesity was not available
in our data. The study by Suleiman et al. [31] did not
find any increased rates of perioperative complications
related to obesity in patients undergoing TKA and THA,
although they did not investigate by arthritis diagnosis.
With RA, we found an expected increase in TJA and co-
morbidity with obesity, although we also found increased
TJA in those who were underweight and a decrease in
mortality in those who were overweight [32]. A similar
protective effect of obesity was found, even after taking
RA diagnosis into account in the Clement et al. study of
mortality after TKA [9], although by keeping body mass
index a continuous measure, they were unable to indicate
whether this was driven by those who were underweight.
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study that found only an increase in TJA with obesity [8].
Conclusions
Although we expected to find greater risk of complica-
tions in RA patients, especially because TJA is reserved
for those with the most-severe disease and therefore
greater risk, our results did not support this in the short
term. Although preoperative risk assessment remains
critical in mitigating postoperative complication, including
infection and cardiovascular events, our results would
suggest that the diagnosis of RA alone should not pre-
clude consideration of this important intervention. Future
studies are needed to elucidate the impact of specific
treatments, obesity, and any additional steps surgeons
may take with RA patients around these increasingly im-
portant surgical procedures.
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